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Abstract
Background: Thousands of long noncoding RNAs (lncRNAs) are aberrantly expressed in various types of cancers,
however our understanding of their role in the disease is still very limited.
Methods: We applied RNAseq analysis from patient-derived data with validation in independent cohort of patients.
We followed these studies with gene regulation analysis as well as experimental dissection of the role of the
identified lncRNA by multiple in vitro and in vivo methods.
Results: We analyzed RNA-seq data from tumors of 456 CRC patients compared to normal samples, and identified
SNHG15 as a potentially oncogenic lncRNA that encodes a snoRNA in one of its introns. The processed SNHG15 is
overexpressed in CRC tumors and its expression is highly correlated with poor survival of patients. Interestingly,
SNHG15 is more highly expressed in tumors with high levels of MYC expression, while MYC protein binds to two E-
box motifs on SNHG15 sequence, indicating that SNHG15 transcription is directly regulated by the oncogene MYC.
The depletion of SNHG15 by siRNA or CRISPR-Cas9 inhibits cell proliferation and invasion, decreases colony formation as
well as the tumorigenic capacity of CRC cells, whereas its overexpression leads to opposite effects. Gene expression
analysis performed upon SNHG15 inhibition showed changes in multiple relevant genes implicated in cancer progression,
including MYC, NRAS, BAG3 or ERBB3. Several of these genes are functionally related to AIF, a protein that we found to
specifically interact with SNHG15, suggesting that the SNHG15 acts, at least in part, by regulating the activity of AIF.
Interestingly, ROS levels, which are directly regulated by AIF, show a significant reduction in SNHG15-depleted cells.
Moreover, knockdown of SNHG15 increases the sensitiveness of the cells to 5-FU, while its overexpression renders them
more resistant to the chemotherapeutic drug.
Conclusion: Altogether, these results describe an important role of SNHG15 in promoting colon cancer and mediating
drug resistance, suggesting its potential as prognostic marker and target for RNA-based therapies.
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Background
In the past years, advances in sequencing revealed that
only 1–2% of the human genome encodes for proteins
while the majority of it is transcribed into non-coding
RNAs (ncRNAs) [1]. Different classes of ncRNAs are
expressed in diverse biological processes and cellular
pathways, including small ncRNAs (miRNAs, piRNAs
and siRNAs) and long ncRNAs, which have at least 200
nucleotides of length and can be spliced [2–5]. LncRNAs
can be classified into various categories based on their
position relative to protein-coding genes: (1) intronic,
when they are located within genes; (2) intergenic, when
they are mapped between different genes and (3) anti-
sense, when they are overlapping with exons of other
transcript on the opposite strand [6]. The functional
roles of these molecules remain mostly unclear, but re-
cent studies have revealed that they contribute to vari-
ous cellular processes such as transcription regulation,
nuclear architecture, epigenetic regulation, enhancer as-
sociation (in nucleus), maintenance of mRNA stability,
sponging microRNA or regulation of protein translation
(in cytoplasm) [7]. Recently, by next-generation sequen-
cing, thousands of lncRNAs have been found to be aber-
rantly expressed in various types of cancers [8]. While
some of them may play oncogenic roles promoting pro-
liferation, invasion and metastasis, others may have a
tumor suppressor function, by modulating growth arrest
pathways [9–11].
According to global cancer statistics, colorectal cancer
(CRC) is the third most common human malignancy
and the fourth leading cause of cancer-associated mor-
tality [12, 13]. Therefore, its early diagnosis is an essen-
tial requirement. Several studies have reported that
some lncRNAs are associated with different stages of
CRC [14, 15], indicating that lncRNAs could be a bio-
marker or target for diagnostic, prognostic and thera-
peutic applications. However, the contribution of long
noncoding RNAs to this type of cancer is still poorly
studied.
In the present study, we identify and characterize the
oncogenic lncRNA SNHG15, which is correlated to sur-
vival of CRC patients. Our results describe an important
effect of SNHG15 in cancerous phenotype of CRC cells
and its role in drug sensitivity. Moreover, several genes
deregulated after SNHG15 depletion are implicated in
cancer initiation, progression and also survival pathways.
Altogether, these findings suggest the potential of




The RNA-seq data of 456 tumor and 41 normal sam-
ples were downloaded from TCGA database (https://
cancergenome.nih.gov/). The expression of lncRNAs
was quantified by Cufflinks v.2.2.1 and lncRNA ex-
pression levels were compared between normal tissue
and tumor tissue samples.
Patients
Fresh CRC specimens and their adjacent normal tissues
were obtained from 36 CRC patients who underwent sur-
geries between 2014 and 2016 in Imam-Reza Hospital,
Mashhad, Iran. None of patients had received preopera-
tive treatment including radiotherapy or chemotherapy
and all of samples were confirmed as colorectal cancer
after histopathological examination. The study protocol
was approved by the Ethics Committee of Ferdowsi Uni-
versity of Mashhad and all patients were informed with a
written for using their tissues. All clinicopathological char-
acteristics of patients are presented in Table 1.
Cell lines and cell culture
Human colorectal cancer cell lines DLD1, HCT 116,
HT-29, LoVo, LS513, SW620 and T84 were cultured in
Roswell Park Memorial Institute (RPMI-1640) medium
(Gibco) supplemented with 10% fetal bovine serum
(FBS, Gibco) and 1% penicillin/streptomycin (Lonza).
RKO, SW480 and Caco-2 cells were cultured in Dulbec-
co’s Modified Eagle Medium (DMEM, Gibco) supple-
mented with 10% FBS and 1% penicillin/streptomycin.
Primary dermal fibroblasts (HDFa) were cultured in
High glucose Dulbecco’s Modified Eagle Medium
(DMEM, Gibco) supplemented with 15% FBS and 1%
Table 1 Clinicopathological characteristics of CRC patients
Clinical parameter Number Percentage
Age
≥ 60 13 36.1
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penicillin/streptomycin. All cell lines were obtained from
American Type Culture Collection (ATCC). Cells were
maintained in 5% CO2 humidified-air at 37 °C.
RNA extraction and qRT-PCR
Total RNAs were isolated from patient specimens and
cultured cells using TRIzol Reagent (Invitrogen) follow-
ing the manufacturer’s instructions. After DNase I (Invi-
trogen) treatment, cDNAs were synthesized using
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystem) with random hexamer primers. qRT-PCRs
were performed using SYBR Green reagent (Applied
Biosystem). Expression levels of genes were calculated
with the comparative cycle threshold (CT) (2-ΔCT
and 2-ΔΔCT) method using glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as an endogenous control. All
primers used in the study are listed in Additional file 1:
Table S1.
Cell transient transfection
All siRNAs for targeting SNHG15 and MYC and nega-
tive control siRNA were purchased from Sigma-Aldrich
(USA). LoVo and SW620 cells were plated into 6 well
plate (150 × 103 cells per well) and transfected with siR-
NAs at a final concentration of 25 nM for 48 h, using Li-
pofectamine 2000 (Invitrogen, USA) according to
manufacturer’s protocol. The sequence of siRNAs are as
follows: SNHG15#1 (Sense: 5′-CCUUGAGUCUCAUG
UUCAA-3′, Anti-sense: 5′- UUGAACAUGAGACU
CAAGG-3′), SNHG15#2 (Sense: 5′- GAGCUUACU
GUCACAGCAA-3′, Anti-sense: 5′- UUGCUGUGA
CAGUAAGCUC-3′), MYC (Sense: 5′- GGUCAGAGU
CUGGAUCACC-3′, Anti-sense: 5′- GGUGAUCCA
GACUCUGACC-3′), Ctrl (Sense: 5′- CAGUCGCGU
UUGCGACUGGC-3′, Anti-sense: 5′- GCCAGUCGC
AAACGCGACUG-3′).
For overexpression of SNHG15, we purchased SNHG15
cDNA sequence (837 bp) was cloned in pDNR-LIB
(BC092459; Source Bioscience-UK) and subcloned it into
pcDNA3.1 plasmid. Then pcDNA3.1 vectors (empty vec-
tor and SNHG15) were transfected into HCT 116 and
SW480 cells (300 × 103 cells per well) at final concentra-
tion 250 ng/mL using Lipofectamine 2000 and subsequent
studies were done after 48 h.
Polysome fractionation
LoVo cells were cultured in 15 cm dishes one day before
experiment to reach 80% confluency. The day after, one
plate was treated with cycloheximide (100 μg/mL) and
another one treated with EDTA (25 mM) to disassemble
the polysomes as negative control followed by incuba-
tion at 37 °C for 5 min. After removing media and wash-
ing 3 times with PBS, cells were harvested by scrapping
and transferred to 15-mL tubes for centrifugation
(200×g for 5 min). Cell pellets were resuspended in
425 μL of a hypotonic buffer [5 mM Tris-HCl (pH 7.5),
1.5 mM KCl, 2.5 mM MgCl2 and 1X protease inhibitor
cocktail], followed by adding 5 μL of 10 mg/mL CHX or
EDTA, 1 μL of 1M DTT and 100 units of RNase inhibi-
tor and vortexed for 5 s. Then 25 μL of 10% Triton
X-100 and 25 μLof 10% sodium deoxycholate were
added and vortexed for 5 s again. Cell lysates were cen-
trifuged at 16000×g for 7 min at 4 °C and supernatants
(~ 500 μl) were loaded onto sucrose gradient. Ultracen-
trifuge was performed at 33000 rpm for 150 min at 4 °C
using Optima L-100 XP Ultracentrifuge (BECKMAN)
with SW41Ti rotor. 12 fractions were separated carefully
and transferred into 2 mL tubes. 1 mL TRIzol Reagent
was added to each fraction and RNA extraction was per-
formed according to manufacturer’s instructions. Ex-
pression levels of SNHG15 in each fraction were
quantified by qRT-PCR and normalized relative to the
first fraction collected. Also GAPDH expression was
evaluated as a translated mRNA (positive control).
Cell proliferation and Colony formation assay
Transfected cells were plated in 96-well plates at a dens-
ity of 1 × 103 cells per well. Then cell proliferation was
evaluated using CellTiter96 Aqueous Non-Radioactive
Cell Proliferation Assay (MTS) kit (Promega) every 24 h.
For colony formation assay, transfected cells (0.5 × 103
cells per well) were seeded in a six-well plate. After 10
days, colonies were fixed with 0.5% Glutaraldehyde
(Sigma) for 20 min and subsequently washed with PBS
for 3 times. Then stained for 30 min with 0.5% crystal
violet (Sigma) and the number of colonies was counted
in each well.
Cell-cycle and apoptosis assays
For cell-cycle analysis, transfected cells were harvested
after 48 h and stained with propidium iodide. Cell cycle
assay was performed in a FACSCalibur flow cytometer
(BD Biosciences) and data were analyzed by BD Cell-
Quest and Flow Jo software. For time-line studies, G1/S
synchronized cells were generated by double thymidine
block procedure. Briefly, cells were grown in medium
containing 2 mM thymidine for 16 h. Then cultured in
normal medium for 9 h followed by 16 h incubation in
presence of 2 mM thymidine again.
Apoptosis assay was performed by Annexin V and
7-AAD staining using Apoptosis Detection Kit I (BD
Biosciences) according to manufacturer’s instructions
and detected by FACSCalibur flowcytometer.
Transwell invasion assay
For invasion assay, the upper side of 8-μm pore-size trans-
well inserts (Corning) were precoated with type I rat tail
collagen (Croning) and then Matrigel (BD, Biosciences)
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was diluted with PBS (3mg/mL) and polymerized at 37 °C
for 2 h. 48 h after transfection, 105 CRC cells (LoVo or
HCT116) in 100 μL of medium containing 1% FBS, were
plated onto the upper side of inserts and after 4 h, 300 μL
of medium containing 10% FBS was added to the lower
chamber to induce cell attraction. Plates were incubated
at 37 °C for 48. Then cells were fixed in 4% formaldehyde
for 20min and non-invading cells on the upper side of the
insert were removed with cotton swabs. The lower part of
the insert was stained with 0.1% crystal violet (Sigma). Im-
ages were captured from four fields in each well using the
Leica DMIL LED inverted microscope (Leica Microsys-
tems) and the numbers of invasive cells were counted
from five random fields in each image. Experiments were
performed independently at least three times.
Mouse xenograft experiments
Female BALB/c-Rag2/−IL2cc/immunodeficient mice aged
6–7 weeks were used in this study. The study was per-
formed under specific pathogen-free conditions at Center
of Medical Application (CIMA) University of Navarra,
Spain. For each mice, 1 × 106 SNHG15 overexpressing
HCT 116 and HCT116 transfected with an empty vector
were resuspended in 100 μL PBS and mixed with the same
amount of Matrigel to inject subcutaneously into the hind
limb. Tumor size was measured externally every 4 days
using a precision caliper for a total period of 28 days.
Tumor volume (V) was estimated using the following for-
mula: V = π/6 × width2 × length. The tumor weight was
measured on the last day after removal.
For LoVo cells, after CRISPR-Cas9 editing, 4× 106 cells
were injected per mice and tumor size was measured
every 4 days. After 48 days, tumors were dissected out
and their weight were measured.
CRISPR-Cas9 editing
Two single-guide RNAs (sgRNAs) were designed to delete
the region between exon 3 to 5 of SNHG15 using a tool
from the Zhang Lab (http://crispr.mit.edu/). Oligonucleo-
tides to clone the guide RNA (Additional file 2: Table S2)
were then annealed and cloned into pX330 vector contain-
ing CAS9 [16] and subsequently co-transfected with GFP
expressing plasmid (pmax-GFP) into LoVo cells. GFP posi-
tive cells were sorted in 96 well plate by BD FACSAria IIu
cytometer. After single cells reached confluency, genomic
DNA was extracted using QuickExtract reagent (Epicentre)
and PCR was performed using a pair of primers flanking
the depleted region and positive clones were identified by
PCR product length. Furthermore, RNA was extracted to
perform qRT-PCR by specific primer (Primer pair 1 and 2)
to validate deletion of aimed region. After selecting clones
(WT3, CL10 and CL83), subsequent experiment (cell pro-
liferation, colony formation, cell cycle, apoptosis assay and
tumor formation) were performed as described before.
Nuclear-cytoplasmic fractionation
Cells were cultured in 10 cm dishes and harvested into
two tubes for subcellular fractions and whole-cell extrac-
tion. After centrifugation at 1000×g for 5 min at 4 °C,
cell pellets were resuspended in 500 μL of lysis buffer
(10 mM Tris-HCl, pH 7.5, 140 mM NaCl, 1.5 mM
MgCl2, 0.05% IGEPAL supplemented with RNasin 10 U/
mL and protease inhibitor cocktail) and incubated on ice
for 10 min. Then TRIzol Reagent was added to one tube
containing cell lysate to extract total RNA. For obtaining
nuclear and cytoplasmic fractions, 500 μL of lysis buffer
containing sucrose was added into a clean tube and cell
lysate was added to this tube without mixing the two
phases. After 10 min centrifugation at 12000×g and 4 °C,
around 500 μL of the upper phase was collected as cyto-
plasmic fraction. Remaining pellet was resuspended in
500 μL of lysis buffer as nuclear fraction and finally cyto-
plasmic and nuclear RNAs were extracted using TRIzol
Reagent.
RNA pull-down
RNA pull-down was performed as described previously
[17]. Briefly, biotinylated RNA of SNHG15 was gener-
ated in vitro and incubated with protein lysate of LoVo
cells and then streptavidin magnetic beads. Interacting
proteins were loaded in a NuPAGE Novex 4–12%
bis-Tris gel (Invitrogen) and stained with SilverQuest
Silver Staining Kit (ThermoFisher). One differential band
was seen and sent for mass spectrometry to Taplin Mass
Spectrometry Facility (Harvard Medical School; USA).
Western blot
Cells were harvested and lysed in RIPA buffer (150 mM
NaCl, 0.5% sodium deoxycholate (Sigma), 0.1% SDS
(Sigma), 50 mM Tris–HCl (pH 7.4), 150 mM NaCl
(Sigma)) containing protease Inhibitor Cocktail (Roche
Applied Science) for 15 min on ice. Cell lysate was cen-
trifuged at 16000×g at 4 °C for 15 min and protein con-
centration was measured by Pierce BCA Protein assay
kit (ThermoFisher). Equal amounts of proteins were
loaded on a 10% SDS-PAG and after separation by elec-
trophoresis, transferred onto nitrocellulose membranes
(Bio-Rad). Membranes were then blocked in 5% non-fat
milk for 1 h at RT and immunoblotted by overnight in-
cubation at 4 °C with the indicated anti-AIF primary
antibody (1:1000; sc-13,116; Santa Cruz). After three
washes with PBS-Tween (0.1%), the membranes were in-
cubated with anti-mouse secondary antibody: anti-IgG
(1:2000; sc-2025; Cell Signaling) for 1 h at RT. Finally,
the protein bands were visualized using an Enhanced
Chemiluminescence Detection kit (Perkin Elmer,
Waltham, MA, USA).
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RNA immunoprecipitation (RIP)
LoVo cells were cultured in 10 cm dishes and then har-
vested to prepare cell lysate by RIPA buffer. After centri-
fugation, cytoplasmic fraction was collected and
pre-cleared with Protein G beads (Invitrogen). Five per-
cent of samples were used as input and remaining were
divided to two parts and incubated with AIF monoclonal
antibody or IgG overnight at 4 °C. RNAs bound to spe-
cific proteins, were separated by Dynabeads protein G
beads (Invitrogen) and extracted by TRIzol. SNHG15
RNA levels were quantified by qRT-PCR using 3 pairs of
SNHG15 primers. MALAT-1, U6, GAPDH and HPRT
were used as negative controls and the data were pre-
sented to the value obtained from IgG.
Immunofluorescence
A density of 75 × 103 LoVo cells were seeded on coverslips
placed in the bottom of each well in 12 well plates. 48 h
after inhibition by siRNAs, cells were fixed in 4% PFA solu-
tion for 30min at RT and then washed with washing buffer.
Non-specific binding was blocked using block solution con-
taining 10% FBS. Cells were incubated in anti-AIF prepared
in block solution (1:250; sc-13,116; Santa Cruz) for 30min
at RT. Then washed two times with washing buffer,
followed by 30min incubation in secondary Alexa fluor 488
donkey anti-mouse IgG (A-21202, Thermo Fisher). Cover-
slips were mounted on slides using mounting solution. All
images were captured using LSM 800 (Zeiss, Jena,
Germany) inverted confocal microscope equipped with a
63x Plan-Apochromat objective (NA1.4 oil).
ROS assay
LoVo cells were transfected with combination of two
si-SNHG15 and si-control. After 48 h, cells were col-
lected and cell lysates were prepared. Cellular ROS level
were measured by OxiSelect in vitro ROS/RNS assay kit
(Cell biolabs) according to the manufacturer’s instruc-
tions, using fluorescence plate reader. Results are shown
as change in relative fluorescence unit (RFU).
Chemotherapy sensitivity assay
24 h after transfection of LoVo or HCT 116 cells, 5 × 103
cells were plated in each well of 96-plates. Plates were
incubated for another 24 h and then treated with 0 to
50 μg/mL of 5-FU (Sigma). Cells proliferation was deter-
mined using CellTiter96 Aqueous Non-Radioactive Cell
Proliferation Assay (MTS) kit (Promega®) every 24 h for
upto 3 days. Viability of the cells was determined by the
following equation: (cells treated with 5-FU Abs/ Un-
treated cells Abs) × 100.
RNA sequencing
LoVo cells were transfected with combination of two
siRNA and control si-RNA. RNA was extracted by
Maxwell 16 LEV simply RNA kit (Promega) from three
biological replicates and the quality of them, were
assessed by High sensitivity RNA ScreenTape system
(Agilent Technologies). Library preparation was per-
formed with the TruSeq Stranded mRNA kit (Illumina).
Libraries were then sequenced on an Illumina NextSeq
(75 bp paired-end). Sequenced reads were aligned using
bowtie2 (against hg19) and the differential gene expres-
sion analysis was carried out with DeSeq2. Biological




All data were analyzed using GraphPad Prism software
(GraphPad Software, version 5.01, CA, USA). Two-tailed
student’s t-test was used to analyze normal distributed data
and differences were considered significant at p < 0.05.
Results
SNHG15 is upregulated in colorectal cancer and is highly
correlated with poor survival
To characterize lncRNAs deregulated in CRC and corre-
lated with survival, we profiled their expression in
Tumor Cancer Genome Atlas (TCGA) cohort of 456 tu-
moral and 41 normal tissue samples. We found 14
lncRNAs as the most significantly deregulated tran-
scripts (Fig. 1a, Additional file 3: Table S3), for which
their upregulation was related to a significant decrease
in survival of CRC patients (Table S3). Among them, we
focused on SNHG15 due to its highly significant upregu-
lation in tumors (p value =7.5e-23) and also the highest
correlation with poor survival of patients (p value =
4e-5) (Fig. 1b). More investigations in this cohort of tu-
mors containing different stages of CRC revealed that al-
though there is a significant upregulation of SNHG15
expression in tumors versus normal samples, there is no
obvious difference among CRC patients at various stages
(Fig. 1c). These results suggest that SNHG15 upregula-
tion is an early event in colorectal cancer promotion and
its expression is maintained at high levels until last
stage.
To confirm this observation, we obtained 36 fresh
colorectal cancer tumors and their adjacent normal tis-
sues immediately after surgery from Iranian CRC pa-
tients (Table 1). SNHG15 expression was examined by
qRT-PCR and its upregulation was observed in tumoral
samples (Fig. 1d, p < 0.001). Moreover, we profiled
SNHG15 expression in ten CRC cell lines (Caco-2,
DLD-1, HCT 116, HT-29, LoVo, LS513, RKO, SW480,
SW620 and T84) and found this lncRNA ubiquitously
expressed in all tested CRC cell lines and with higher
levels compared to the non-cancerous HDFa cell line
(Fig. 1e).
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SNHG15 expression is regulated in the cell cycle and
transcriptionally controlled by MYC
SNHG15 (small nucleolar RNA host gene 15) is located
on chromosome 7 and composed of 5 exons. According
to GENCODE V29 annotation, it can be spliced into dif-
ferent isoforms, although isoform 2 is the most abundant
[18]. Interestingly, SNORA9 (small nucleolar RNA, H/
ACA box 9) is encoded in intron 2 of SNHG15 (Fig. 2a).
SNORA9 also named ACA9 is a member of H/ACA pseu-
douridylation guide RNA machinery, which contributes to
pseudouridine synthesis in snRNAs and rRNAs [19]. Cod-
ing potential analysis revealed that SNHG15 sequence
does not have ability to code for proteins (Fig. 2b). In
agreement with this, polysome fractionation methods
revealed that SNHG15 is not associated with polysomes
(Additional file 4: Figure S1).
Previous studies revealed that there are two E-box
(CACGTG) binding motifs for transcription factor MYC
on the first exon and first intron of SNHG15 [20]. We
therefore analyzed ChIP-seq data from ENCODE and
confirmed that MYC is bound to these boxes in different
cancerous cell lines (Fig. 2c).
In order to investigate the transcriptional regulation of
SNHG15 by MYC, we analyzed colorectal adenocarcin-
oma RNA-seq data from TCGA, finding that SNHG15 is
significantly upregulated in the tumors with high level of
MYC expression (Fig. 2d). In agreement with this obser-
vation, the depletion of MYC in LoVo CRC cell line
Fig. 1 a Expression of candidate lncRNAs deregulated in CRC tumors compared to normal samples and with higher expression significantly
correlated with decreased survival of patients analyzed by RNA-seq from The Cancer Genome Atlas (TCGA). P values were calculated using
Wilcoxon signed rank test. b Kaplan–Meier analyses of the correlations between SNHG15 expression level and overall survival of 450 patients with
CRC (TCGA). c SNHG15 expression levels in different stages of CRC compared with normal tissues (TCGA). d Relative expression level of SNHG15 in
36 Iranian CRC patients compared with corresponding adjacent tissue. P-value is calculated by two-tailed Student’s t-test. e Expression levels of
SNHG15 in a panel of CRC cell lines in comparison with HDFa cells as a normal cell line. Data are shown as mean ± SD
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resulted in a significant decrease in the level of SNHG15
(Fig. 2e). These results indicate that SNHG15 transcrip-
tion is controlled by MYC.
Since MYC is well known to regulate cell cycle, we in-
vestigated expression of SNHG15 during cell cycle. To
do this, we obtained G1/S synchronized cells by double
thymidine block procedure and collected the cells at dif-
ferent time points after block release. Results showed
that SNHG15 expression is regulated during the cell
cycle, with an increased expression of SNHG15 in G2/M
phase (Additional file 5: Figure S2). Together, these data
suggest that SNHG15 is transcriptionally regulated by
MYC in a cell-cycle dependent manner.
SNHG15 deregulation has strong effects on proliferation,
invasion and tumor formation abilities of CRC cells
To investigate SNHG15 function in CRC, we designed
two siRNAs to knock it down, and transfected LoVo
and SW620 cells with each one of them individually
or a combination of both. qRT-PCR analysis showed
that 48 h after transfection, SNHG15 transcript was
significantly reduced, while the expression level of
SNORA9, which is located in one of its introns, was
not changed (Fig. 3a and c). These results confirmed
that the designed siRNAs target SNHG15 exons after
splicing, leaving intact SNORA9, and allowing study-
ing SNHG15 function independently of SNORA9. Fur-
ther investigation showed that the knockdown of
SNHG15 significantly inhibited cell proliferation (Fig.
3b and d) and colony formation capacity of these
cells (Fig. 3e-f ). However, downregulation of SNHG15
did not significantly influence the cell cycle profile or
the percentage of apoptotic cells (Fig. 3g-h). On the
other hand, the invasion capacity of the cells was sig-
nificantly decreased after SNHG15 inhibition, as quan-
tified by transwell assays (Fig. 3i-j).
We subsequently investigated the effects of SNHG15
overexpression on cell growth, invasion and tumor
formation capacity. To do so, SNHG15 cDNA se-
quence (837 bp) was cloned and expressed transiently
in HCT 116 and SW480 cells, which express SNHG15
at lower levels compared to LoVo and SW620 cells.
qRT-PCR analysis indicated a significant increase in
SNHG15 RNA levels relative to the control cells
transfected with the empty vector (Fig. 4a and d).
MTS assay showed that the enforced expression of
SNHG15 led to a significant increase in cell prolifera-
tion (Fig. 4b and e). Colony formation assay also
Fig. 2 a Genomic locus of SNHG15 and its different transcript variants annotated in Gencode V29. The most highly expressed variant is shown in
dark blue. b Coding potential of SNHG15 in comparison with GAPDH (as a coding-protein gene) determined with coding potential assessment
tool (CPAT). c Location of the E-box biding motifs in the SNHG15 sequence and MYC binding to these regions confirmed by ChIP-seq in different
cancerous cell lines. d Expression of SNHG15 in CRC tumors with high or low MYC expression (TCGA). Significance was determined by unpaired
student’s t-test (p value < 0.001). e SNHG15 RNA level after depletion of MYC in LoVo cells. p value is calculated by two-tailed Student’s
t-test (p value < 0.01)
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Fig. 3 a SNHG15 and SNORA9 RNA level after knockdown with the two siRNAs separately or in combination in LoVo cells. b Cell proliferation
measured by MTS assay after inhibition of SNHG15 in LoVo cells. c SNHG15 and SNORA9 expression levels in SW620 cells after inhibition of SNHG15
with siRNAs. d Proliferation capacity of SW620 after SNHG15 knockdown. e The results of colony formation assay performed quantified after 10 days of
inhibition in LoVo cell line and (f) in SW620 cell line. g Cell-cycle phase distribution of LoVo cells determined by propidium iodide-staining (h)
Percentage of apoptotic LoVo cells after staining with annexin V and 7-AAD (i) Number of LoVo cells invading through the membrane under the
indicated conditions in the transwell assay. j Invading LoVo cells stained on transwell chambers after 48 h in each condition. The statistical analysis is
performed by two-tailed Student’s t-test and graphs shows mean ± SEM of values (*p < 0.05, **p < 0.01, ***p < 0.001)
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indicated that SNHG15-overexpressing cells not only
could form more colonies but also of larger size (Fig.
4c and f ). Consistently with the phenotype observed
upon depletion, SNHG15 overexpression did not in-
fluence cell cycle or apoptosis in HCT 116 cells (Fig.
4g-h). In addition, the overexpression of SNHG15 in
HCT 116 cells increased their invasion capacity (Fig. 4i).
To further explore the role of SNHG15 in the
tumorigenicity of CRC cells, SNHG15-overexpressing
and control HCT 116 cells were injected into
immunodeficient mice, and the tumor size was mea-
sured every 4 days. As shown in Fig. 4j, tumors grew
faster in cells overexpressed SNHG15, and larger and
heavier tumors were formed by these cells after 4
weeks.
In order to confirm our results and exclude possible off
target effects of the siRNAs, we knocked-out SNHG15 by
CRISPR-Cas9 system in LoVo cells. Two guide RNAs
(gRNAs) were designed to delete a region of SNHG15 of
around 1400 bp without affecting SNORA9 sequence
Fig. 4 a Level of SNHG15 after overexpression in HCT116 cells determined by qRT-PCR (b) Change in proliferation ability of HCT116 cells after
overexpression of SNHG15 in comparison with control. c Colony formation ability in overexpressing cells comparing to control cells. d SNHG15
RNA level after Transfection SW480 cells with SNHG15-vector via Empty vector. e Change in cell proliferation ability after SNHG15 overexpression
in SW480 cell line. f Results of colony formation assay after overexpressing SNHG15 in SW480 cells. g Cell cycle analysis in HCT 116 cells after
overexpression of SNHG15 using propidium iodide staining. h Percentage of apoptotic HCT 116 cells determined by annexin V and 7-AAD
staining. i Invasion ability of HCT116 cells after overexpression of SNHG15. j Tumor formation in immunodeficient mice of the same cell lines (n =
7). P value is calculated by two-tailed Student’s t-test and graphs shows mean ± SEM of values (*p < 0.05, **p < 0.01, ***p < 0.001)
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(Fig. 5a). Several clones were obtained with homozygote
deletion. After screening of the clones, we chose two
independent clones with deletion in the aimed region
confirmed by qRT-PCR with two pairs of primer de-
signed specifically for deleted and non-deleted region.
Of note, they no changes in SNORA9 expression were
observed (Fig. 5b). The experimental characterization
of these two clones showed their low proliferation
and colony formation capacity (Fig. 5c, d), while
didn’t show significant changes in cell cycle profile
and percentage of apoptotic cells (Fig. 5e-f ). More-
over, xenograft mice model experiments confirmed
our previous data and revealed that the tumors
formed by knock-out cells were smaller and lighter
Fig. 5 a Schematic representation of CRISPR/Cas9 technology to delete the region between exons 3 to 5 of SNHG15 and annealing sites
of primers to detect deleted and non-deleted regions on RNA. b Relative RNA level for deleted, non-deleted region and SNORA9 from
wild type (no. 3) and homozygote clones (no. 10 and no. 83) with the different primer sets. c Cell proliferation, d colony formation
ability after knockout of SNHG15. e Cell cycle profile and (f) Percentage of apototic cells. g Tumor formation capacity after deletion of
exons 3 to 5 of SNHG15 in LoVo cells. The statistical analysis is performed by two-tailed Student’s t-test and graphs shows mean ± SEM of
values (*p < 0.05, **p < 0.01, ***p < 0.001)
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than those formed by the wild type cells (Fig. 5g).
Together, these results suggest that SNHG15 pro-
motes the oncogenic capacity of CRC cells.
SNHG15 depletion in CRC cells affects the expression of
genes with roles in cell proliferation, migration and
survival
To determine the biological processes and pathways reg-
ulated by SNHG15, a gene expression analysis by
RNA-seq was performed in LoVo cells after transfection
with combination of two siRNAs or a negative control
siRNA. Our results revealed an elevated number of
genes significantly deregulated upon SNHG15 depletion
(Fig. 6a – Additional file 6: Table S4). Among 766 genes
with a significant change of expression (FDR < 0.05), 372
genes were upregulated and 394 genes were downregu-
lated. In order to obtain more information about
SNHG15 function, Ingenuity Pathway Analysis (IPA) was
performed, showing that the genes affected by SNHG15
knockdown are preferentially associated to cancer as
well as cell death and survival (Fig. 6b). Interestingly,
more detailed canonical pathway analysis showed that
these genes contribute to some important molecular
pathways and mechanisms of cancer, including poly-
amine regulation in colon cancer, GADD45 signaling,
chromosomal replication during cell cycle and role of
CHK protein in cell cycle checkpoint control (Fig. 6c).
We chose 20 candidates among the genes detected by
the RNA-seq and pathway analyses to validate the
changes in their expression caused by SNHG15 deple-
tion. Results showed that CTGF, GADD45A, GADD45B,
HAS2, LAMC3, NRAS, BAG3, ERBB3, MYC and CASP3
were deregulated after SNHG15 inhibition with each in-
dividual siRNA or by the combination of them (Fig. 6c),
confirming the effect of SNHG15 in the regulation of
these relevant genes.
SNHG15 interacts with AIF in the cytoplasm and
contributes to the resistance to stress
The gene expression analysis performed reflected the
physiological changes caused by SNHG15 downregulation
in CRC cells in terms of proliferation and tumorigenicity.
However the analysis did not provide insights into the
mechanism by which SNHG15 affects the biology of the
tumor cells. To investigate the mechanism by which
SNHG15 regulates CRC proliferation, we first set to deter-
mine its subcellular localization. Nuclear-cytoplasmic frac-
tionation in LoVo cells showed that this lncRNA is mainly
cytoplasmic (Fig. 7a). We hypothesized that SNHG15 in-
teracts with cytoplasmic proteins to carry out its func-
tions, so we focused on identifying specific physical
interactions with SNHG15. To that end, we performed
RNA pull-down using in vitro transcribed SNHG15 RNA
or an unrelated RNA of similar length (murine linc-p21)
as control. The RNAs were incubated with cytoplasmic
extract of LoVo cells and mass spectrometry (MS) was
performed on the differential band found on the retained
proteins (Fig. 7b, upper panel). Apoptosis Induced Factor
(AIF) was identified as a protein bound to SNHG15 with 8
unique peptides but absent in the control RNA pull-down.
AIF is a bifunctional protein that exhibits distinct roles
based on its subcellular localization. After translation in
the cytosol AIF is transported to the mitochondria, where
it acts as an NADH oxidase to generate O2
− and subse-
quently H2O2 [21]. In consequence, AIF has an effect on
reactive oxygen species (ROS) levels with a strong impact
in various cellular stress and survival pathways [22, 23].
On the other hand, upon apoptotic stimulus AIF can be
cleaved and translocated to the nucleus, where it binds to
DNA and promotes chromatin condensation and DNA
fragmentation, which are necessary for the apoptosis pro-
gram [24]. Interestingly, the molecular weight of the iso-
form that we found as interacting with SNHG15 is around
67 kDa (full length protein), indicating that SNHG15 binds
to the precursor AIF.
The interaction between SNHG15 and AIF was further
validated by western blot using specific antibody against
AIF (Fig. 7b). Moreover, it was confirmed by RNA im-
munoprecipitation (RIP) with an antibody able to specif-
ically immunoprecipitate the endogenous AIF (Fig. 7c).
To further investigate the functional relationship be-
tween SNHG15 and AIF, immunofluorescence studies
were performed showing that inhibition of SNHG15 did
not change AIF subcellular localization from cytoplasm
to nucleus (Fig. 7d), suggesting that SNHG15 is not im-
plicated in the pro-apoptotic function of AIF.
Based on these observations and the phenotype ob-
served in the cells upon SNHG15 inhibiton, we hypothe-
sized that SNHG15 binding to AIF does not influence AIF
role in apoptosis, but may affect the other mechanism in
which the protein has been involved, i.e. respiratory chain
and stress response [22, 23]. To test this hypothesis, we
measured ROS levels in SNHG15-depleted cells in com-
parison to controls. As shown in Fig. 7e, after depletion of
SNHG15, ROS levels resulted in a significant reduction.
Since enhancement of ROS is known to prevent cellular
toxicity by neutralizing chemical stresses [22, 23], we ex-
amined whether the expression of SNHG15 had an influ-
ence on survival of CRC cells after treatment with 5-FU as
chemical stress. To do this, we depleted or overexpressed
SNHG15 in CRC cells (LoVo or HCT 116) and exposed
them to different concentrations of 5-FU (0 to 50 μg/mL).
After 48 h of drug treatment, the results on proliferation
assay showed that SNHG15 levels had a significant influ-
ence on the response of CRC to 5-FU at 8 μg/mL. At this
concentration, SNHG15-depleted cells were more sensi-
tive to 5-FU and their viability was lower compared to
control cells. On the other hand, SNHG15-overexpressing
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cells showed more resistance and higher survival to the
drug treatment than control cells (Fig. 7f). These results
suggest that the increased levels of SNHG15 are related
with the capacity of CRC cells to cope with the cytotoxic
stress caused by 5-FU, which could be mediated by its
interaction with AIF. In agreement with these findings,
Fig. 6 a Heatmap representation of genes deregulated after SNHG15 depletion by siRNA in LoVo cells (p value < 0.01). b Molecular and cellular
functions and diseases associated with these genes. P values are the min and max p values of the enriched categories within a general category
that appears in the data Table. c Top canonical pathways changed after depletion of SNHG15 recognized by IPA. d qRT-PCR analysis for RNA-seq
validation on the genes selected from RNA-seq and pathway analysies. P value is calculated by two-tailed Student’s t-test and graphs shows
mean ± SEM of values (*p < 0.05, **p < 0.01, ***p < 0.001)
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pathway analysis on the genes affected by SNHG15 knock-
down revealed that many of them are functionally related
to AIF. Moreover, the role of this group of genes in many
important cellular mechanisms such as tissue morphology,
cell death and survival, cellular growth and proliferation,
cell cycle, organismal development and cellular movement
(migration) was confirmed. It was also revealed that these
genes contributed in some disorder like cancer, gastro-
intestinal disease, organismal injury and abnormalities
(Fig. 7g).
Discussion
Since colorectal cancer is the third most common hu-
man malignancy worldwide [13], many researchers have
focused on the characterization of CRC-related lncRNAs
as new biomarkers for diagnosis or targeted therapy of
this disease. Some of these important lncRNAs include
CCAT1, H19, HOTAIR, MALAT1, UCA1 and PTENP1
[14, 25]. In this study, we searched for lncRNAs strongly
associated with poor prognosis of CRC. SNHG15 was
identified as an oncogenic lncRNA whose upregulation
Fig. 7 a RNA levels of SNHG15 and control RNAs in nuclear and cytoplasmic fractions measured by qRT-PCR. The statistical analysis is performed
by two-tailed Student’s t-test b Top: Silver stained gel with the proteins retained in the RNA pull-down experiment by SNHG15 and linc-p21 as
negative control (CN), the differential band analyzed by mass spectrometry is indicated by an arrowhead; bottom: detection of the AIF protein by
western blot in a replicate of the RNA pull-down experiment. c RNA immunoprecipitation using AIF monoclonal antibody and followed by qRT-
PCR using three different primer pairs for SNHG15, and MALAT-1, U6, GAPDH and HPRT as negative controls. d AIF localization after SNHG15
inhibition using immunofluorescence antibody. Nuclei were stained with DAPI. e ROS levels of in LoVo cells transfected with the indicate siRNAs
(p value< 0.05). f Cell viability determined by MTS of CRC cells (LoVo and HCT 116) after depletion or overexpression of SNHG15 treated with
8 μg/mL for 48 h (p value< 0.001). g Connection between AIF and the genes validated with most important pathway recognized. The statistical
analysis is performed by two-tailed Student’s t-test and graphs shows mean ± SEM of values
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was related to poor survival of CRC patients. Interest-
ingly, the classification of colorectal adenocarcinoma
TCGA samples relative to MYC expression showed that
SNHG15 is upregulated in the samples with high levels
of MYC expression. More investigation confirmed that
MYC has two binding sites (E-box) on SNHG15 se-
quence and bound them in different cancerous cell lines.
Furthermore, its inhibition by siRNA, led to decrease
SNHG15 level in CRC cell line and confirmed that
SNHG15 is transcriptionally regulated by MYC. On the
other hand, RNA-seq results showed significant reduc-
tion of MYC transcript after depletion of SNHG15.
These finding suggest a feedback loop between SNHG15
and MYC expression that introduce SNHG15 as an add-
itional component of the pro-proliferative network acti-
vated by this oncogenic transcription factor.
Consistently with this notion, the depletion of SNHG15
by different experimental methods leads to decreased
cell proliferation, while its enforced expression promotes
cell proliferation and clonogenicity.
Long non-coding RNAs have been involved in a variety
of mechanisms that can take place in different cellular
compartments. Although some studies have addressed the
role of SNHG15 in the nucleus [18], in LoVo cells
SNHG15 is mainly localized in the cytoplasm, suggesting
that it has a role in this cellular compartment. To eluci-
date the role of SNHG15, we searched for proteins with
specific physical interactions with SNHG15, identifying
AIF as associated with SNHG15. AIF mRNA is translated
in the cytoplasm into a 613-amino acid precursor (67
kDa) that is transported to mitochondria via mitochon-
drial localization signal (MLS). After being imported into
the intermembrane space, the first 34 amino acids are re-
moved and the 62 kDa mature AIF (AIFmit) is generated
to contribute to the respiratory chain as an NADH oxi-
dase [21, 26]. If cells receive an apoptotic stimulus, a dif-
ferent cleavage occurs in AIFmit by calpain or cathepsin,
and a 57 kDa AIF is formed to induce DNA condensation
and DNA fragmentation in the nucleus [27–29].
It has been shown that AIF maintains the transformed
state of CRC cells via its NADH oxidase activity and
cells show more apoptosis sensitivity as a result of AIF
knockout and decreases in ROS level. In other words,
AIF helps to neutralize chemical stress, and increased
protein level of AIF leads to enhancement of ROS to
prevent cellular toxicity [22, 23]. Interestingly, we did
not observe significant changes in the number of apop-
totic cells after dysregulation of SNHG15. In addition,
inhibition of SNHG15 did not induce translocation of
AIF into nucleus after 48 h. These data suggest that
under these experimental conditions, i.e. in the absence
of apoptotic stimulus, SNHG15 mainly affects the
oxidation-related function of AIF. Given the full-length
size of the AIF protein interacting with SNNH15, and
the subcellular localization of the lncRNA, we speculate
that SNHG15 could interact with AIF upon the protein
translation, coupling it to its correct translocation to the
mitochondria. Interestingly, many studies have demon-
strated that several members of the HSP70 family could
bind to AIF and neutralize this protein [30]. Gurbuxani
et al. showed that fragment between amino acids 150 to
228 of AIF is necessary for binding to HSP70 and this
interaction block AIF nuclear localization [31]. As this
fragment exists in both isoform of AIF, this process may
occur for mitochondrial localization, so it is possible that
binding SNHG15 to AIF could prevent AIF
neutralization by HSP70 family and help it to translocate
to intermembrane space of mitochondria for contribut-
ing in respiratory chain activities and stress response. In
agreement with our observations, previous studies have
shown that SNHG15 contribute to the molecular mech-
anism of cellular stress response. This lncRNA is a
short-lived lncRNA (t1/2 < 4 h) and its expression level
is increased significantly after 24 h cycloheximide used
as a stressor, when its half-life was increased from 3.4 to
more than 24 h after this treatment [32]. We showed
that after depletion of SNHG15, ROS levels are signifi-
cantly decreased, and drug sensitivity experiments
showed that inhibition of SNHG15 could sensitize CRC
cells to 5-FU, which is a basic chemotherapeutic drug
for CRC. Based on these results, we propose that the
interaction between AIF and SNHG15 may be help to in-
corporate this protein in ROS formation pathway.
Gene expression analysis after depletion of SNHG15
revealed significant deregulation of multiple genes in-
cluding CTGF, GADD45A, GADD45B, HAS2, LAMC3,
NRAS, BAG3, ERBB3, MYC and CASP3. Most of these
genes are known to play an important role in CRC
tumor development and response to treatment. For ex-
ample, CTGF decreases cell apoptosis and enhances
CRC chemoresistance to 5-FU [33]. The inhibition of
GADD45A leads to decrease in DNA repair and sensitize
cells to ultraviolet-irradiation or cisplatin [34], while
high level of its expression, turns CRC cells resistant to
treatment with oxidative stress-inducing compounds
[35]. GADD45B is significantly upregulated in CRC, and
high levels of GADD45B expression are related to poor
survival of patients [36]. Similarly, HAS2 [37, 38], NRAS
[39, 40] and BAG3 [41–43] have well-established roles in
CRC carcinogenesis and response to chemotherapy.
Therefore, the gene expression changes linked to the
loss of SNHG15 are affecting central oncogenic path-
ways, including the response to chemotherapy and drug
response, which is directly related of AIF function. How-
ever we cannot exclude that SNHG15 has additional
functions in the cell. For instance, SNHG15 has been re-
ported to control Slug stability in the nucleus [18] or
regulate the levels of certain microRNAs [44–46]. It
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remains to be shown if the combination of other mecha-
nisms with the AIF-dependent here described confers
SNHG15 its full pro-oncogenic activity.
Beyond CRC, the dysregulation and oncogenic role of
SNHG15 has been indicated in various types of cancer,
including gastric [47] and hepatocellular carcinoma [48],
osteosarcoma [44], as well as pancreatic [49] and breast
cancers [46]. Our study, together with this body of work,
including a recent study relating this lncRNA with in-
creased liver metastasis of CRC tumors [50], indicate
that SNHG15 possesses a broad oncogenic activity, and
suggests that the development of tools to target the
lncRNA could have therapeutic value across multiple
cancer types.
Conclusion
Our results describe a role for the MYC-regulated
SNHG15 locus in colorectal cancer, role dependent on
the lncRNA encoded by this bifunctional gene. The
lncRNA SNHG15 is able to promote colon cancer and
mediating drug resistance, suggesting its potential as
prognostic marker and target for RNA-based therapies.
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